Circulating myeloid-derived suppressor cells in patients with pancreatic cancer
XD Xu, J Hu, M Wang, F Peng, R Tian, XJ Guo… - … & Pancreatic Diseases …, 2016 - Elsevier
Background Myeloid-derived suppressor cells (MDSCs) are heterogeneous cell types that
suppress T-cell responses in cancer patients and animal models, some MDSC
subpopulations are increased in patients with pancreatic cancer. The present study was to
investigate a specific subset of MDSCs in patients with pancreatic cancer and the
mechanism of MDSCs increase in these patients. Methods Myeloid cells from whole blood
were collected from 37 patients with pancreatic cancer, 17 with cholangiocarcinoma, and 47 …
suppress T-cell responses in cancer patients and animal models, some MDSC
subpopulations are increased in patients with pancreatic cancer. The present study was to
investigate a specific subset of MDSCs in patients with pancreatic cancer and the
mechanism of MDSCs increase in these patients. Methods Myeloid cells from whole blood
were collected from 37 patients with pancreatic cancer, 17 with cholangiocarcinoma, and 47 …
Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy
A Romano, NL Parrinello, C Vetro… - British journal of …, 2015 - Wiley Online Library
In the attempt to find a peripheral blood biological marker that could mirror the dysregulated
microenvironment of Hodgkin Lymphoma (HL), we analysed the amount of myeloid‐derived
suppressor cells (MDSC), including the three main sub‐types (monocytic, granulocytic and
CD 34+ fraction). The absolute MDSC count was investigated in 60 consecutive newly
diagnosed HL patients and correlated with clinical variables at diagnosis and outcome.
Patients received standard‐of‐care chemotherapy with the exception of interim …
microenvironment of Hodgkin Lymphoma (HL), we analysed the amount of myeloid‐derived
suppressor cells (MDSC), including the three main sub‐types (monocytic, granulocytic and
CD 34+ fraction). The absolute MDSC count was investigated in 60 consecutive newly
diagnosed HL patients and correlated with clinical variables at diagnosis and outcome.
Patients received standard‐of‐care chemotherapy with the exception of interim …